The NeoWave portfolio uses the company’s Nanoactiv surface tecnology and is designed for cervical and lumbar innterbody spinal fusions, according to a news release. More than 7,000 devices have been implanted in the U.S.
“Receiving nanotechnology clearance for the neoWave interbody systems is an incredible milestone and achievement for Xēnix, elevating the neoWave implant systems into a distinct device category shared only by a few companies in the industry,” Xēnix Medical CEO Ryan Phillips said in the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
